Dextrose And Sodium Chloride (dextrose monohydrate and sodium chloride) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Dextrose And Sodium Chloride - Dextrose Monohydrate And Sodium Chloride injection, Solution

    Get your patient on Dextrose And Sodium Chloride - Dextrose Monohydrate And Sodium Chloride injection, Solution (Dextrose Monohydrate And Sodium Chloride)

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Dextrose And Sodium Chloride - Dextrose Monohydrate And Sodium Chloride injection, Solution prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    Intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    The dose is dependent upon the age, weight and clinical condition of the patient.

    As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS .

    Drug Interactions

    Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

    Contraindications

    CONTRAINDICATIONS

    None known.

    Adverse Reactions

    ADVERSE REACTIONS

    Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

    Description

    DESCRIPTION

    Dextrose and Sodium Chloride Injection, USP solutions are sterile and nonpyrogenic. They are large volume parenteral solutions containing various concentrations and combinations of these drugs in water for injection intended for intravenous administration.

    See Table for summary of content and characteristics of these solutions.

    The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

    The solutions are parenteral fluid, nutrient and electrolyte replenishers.

    Dextrose, USP is chemically designated D-glucose monohydrate (C 6 H 12 O 6 • H 2 O), a hexose sugar freely soluble in water. It has the following structural formula:

    Referenced Image

    Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

    Water for Injection, USP is chemically designated H 2 O.

    The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

    Pharmacology

    CLINICAL PHARMACOLOGY

    When administered intravenously, these solutions provide a source of water, carbohydrate and electrolytes.

    Solutions which provide combinations of hypotonic or isotonic concentrations of dextrose and of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements with minimal carbohydrate calories.

    Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

    Sodium chloride in water dissociates to provide sodium (Na + ) and chloride (Cl¯) ions. Sodium (Na + ) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl¯) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na + ) and chloride (Cl¯) are largely under the control of the kidney which maintains a balance between intake and output.

    Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na + ) plays a major role in maintaining physiologic equilibrium.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    Dextrose and Sodium Chloride Injection, USP are supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table.

    Content and Characteristics

    Grams/100 mL

    Per 1000 mL

    NDC No.

    Product

    Dextrose

    (hydrous)

    Sodium

    Chloride

    Sodium

    Na +

    Chloride

    Cl¯

    Caloric

    Value

    Tonicity

    Osmolarity mOsmol/L (calc)

    pH

    Container

    size (mL)

    0409-7924-02 Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA
    0990-7924-02

    5% Dextrose and 0.225% Sodium Chloride Inj., USP

    5

    0.225

    38.5 mEq

    38.5 mEq

    170

    Hypertonic

    329

    4.3 (3.5 to 6.5)

    250

    0409-7924-03 Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA
    0990-7924-03 ,

    5% Dextrose and 0.225% Sodium Chloride Inj., USP

    5

    0.225

    38.5 mEq

    38.5 mEq

    170

    Hypertonic

    329

    4.3 (3.5 to 6.5)

    500

    0409-7924-09 ,
    0990-7924-09 ,

    5% Dextrose and 0.225% Sodium Chloride Inj., USP

    5

    0.225

    38.5 mEq

    38.5 mEq

    170

    Hypertonic

    329

    4.3 (3.5 to 6.5)

    1000

    0409-7925-03
    0990-7925-03 ,

    5% Dextrose and 0.3% Sodium Chloride Inj., USP

    5

    0.3

    51 mEq

    51 mEq

    170

    Hypertonic

    355

    4.3 (3.5 to 6.5)

    500

    0409-7925-09 ,
    0990-7925-09 ,

    5% Dextrose and 0.3% Sodium Chloride Inj., USP

    5

    0.3

    51 mEq

    51 mEq

    170

    Hypertonic

    355

    4.3 (3.5 to 6.5)

    1000

    0409-7926-02
    0990-7926-02

    5% Dextrose and 0.45% Sodium Chloride Inj., USP

    5

    0.45

    77 mEq

    77 mEq

    170

    Hypertonic

    406

    4.3 (3.5 to 6.5)

    250

    0409-7926-03
    0990-7926-03 ,

    5% Dextrose and 0.45% Sodium Chloride Inj., USP

    5

    0.45

    77 mEq

    77 mEq

    170

    Hypertonic

    406

    4.3 (3.5 to 6.5)

    500

    0409-7926-09 ,
    0990-7926-09 ,

    5% Dextrose and 0.45% Sodium Chloride Inj., USP

    5

    0.45

    77 mEq

    77 mEq

    170

    Hypertonic

    406

    4.3 (3.5 to 6.5)

    1000

    0409-7941-03
    0990-7941-03 ,

    5% Dextrose and 0.9% Sodium Chloride Inj., USP

    5

    0.9

    154 mEq

    154 mEq

    170

    Hypertonic

    560

    4.3 (3.5 to 6.5)

    500

    0409-7941-09 ,
    0990-7941-09 ,

    5% Dextrose and 0.9% Sodium Chloride Inj., USP

    5

    0.9

    154 mEq

    154 mEq

    170

    Hypertonic

    560

    4.3 (3.5 to 6.5)

    1000

    ICU Medical is transitioning NDC codes from "0409" to "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.

    Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

    Revised: August, 2020

    IFU0000261

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Dextrose And Sodium Chloride - Dextrose Monohydrate And Sodium Chloride injection, Solution PubMed™ news

      Show the latest PubMed™ articles for Dextrose And Sodium Chloride - Dextrose Monohydrate And Sodium Chloride injection, Solution